Toggle navigation
Home
Ask A Question
Answer Questions
Users
Support/FAQ
Login
Register
Preview 50% of the Answer Below
Due to formatting, images, tables, or paragraphs may be out of place or not shown. Rest assured that they will be included and formatted correctly in your purchased answer.
Details
Question Title:
Health Care
Go Back to the Question
Answer Preview
Biotechnology Organization: Motif Bio</span></p> <p><span class="s1"></span> </p> <p><span class="s1" <this="" essay="" will="" discuss="" the="" mission="" statement="" of="" motif="" bio,="" a="" clinical-stage="" biopharmaceutical="" company="" that="" serves="" as="" researcher="" and="" manufacturer="" antibiotic="" drugs="" combat="" multi-drug="" resistant="" bacteria,="" well="" activities="" organization="" role="" this="" plays="" in="" u.s.="" healthcare="" system.=""></span></p>This essay will discuss the mission statement of Motif Bio, a clinical-stage biopharmaceutical company that serves as a researcher and manufacturer of antibiotic drugs that combat multi-drug resistant bacteria, as well as the activities of the organization and the role that this organization plays in the U.S. healthcare system.<p></p><p><br></p><p></p><p><span class="s1">The mission of Motif Bio is to create novel antibiotics that are effective against infections caused by multi-drug resistant Gram-positive bacteria, such as MRSA. The company’s mission is especially timely, given the rapid increase in multi-drug resistant bacteria cases such as MRSA due to an increase in the misuse of antibiotics, and a growth in the complexity of the bacterial mutation environment. (Motif Bio, 2015)</span></p> <p><span cXXXX="s1"></span> </p> <p><span XXXXX="s1" <XXX="" organization’s="" main="" XXXXXXXXXX="" are="" in="" research="" and="" development,="" clinical="" trials,="" XXXXXXXXXX,="" distribution,="" XXXXXXXXXXXXX,="" XXXXXXXX="" talent="" recruitment.="" XXXXXXXX,="" the="" XXXXXXX="" invests="" XXXXXXX="" especially="" XXXXXXX="" its="" XXXX="" product="" XXXXXXXXX="" of="" XXXXXXXX,="" XXX="" XXXX="" XXXX="" as="" XXXXX="" bacterial="" XXXX="" XXXXXXXXX="" XXXXXXXXXX="" (XXXXXX),="" hospital="" acquired="" XXXXXXXXX="" (XXXX),="" ventilor="" XXXXXXXXXX="" (XXXX).="" (motif="" bio,="" 2019)="" then="" conducts="" XXXXXX="" to="" ensure="" these="" XXXXXXXX="" XXXX="" administration="" patients="" XXXXXXXXXX="" XXXX="" XXXXXXXXX.="" XXXXXXX,="" XXXX,="" has="" conducted="" XX="" nearly="" 1,500="" healthy="" volunteers="" XXXXXX="" XXXXXXX="" effectiveness="" XXXX-XXXXXXX="" drug="" candidate.="" include="" XXXXXX-X,="" revive-X="" XXXXXXX="" which="" absssi,="" habp="" vabp="" respectively.="" also="" XXXXXXXX="" distributes="" drugs,="" XX="" XXXXXXXXXXX="" XXXX,="" efficient="" cost-XXXXXXXXX="" XXXXXXXXXX="" XXXXXXXXXXXX="" XXXXX="" XXXXXXXXXXXX="" clinics="" XXXXXXXXX.="" XXXXX="" XXXXXXX="" XXXX="" they="" XXX="" be="" distributed="" legally,="" certification="" processes="" XXXXXXXXX="" infectious="" disease="" (XXXX)="" XXX="" XXXXXXXXXXXXX.="" XXXX)="" XXXX,="" XXXXX="" properly="" XXXXXXXXXX="" public="" acceptance,="" XXXXX="" linkedin="" XXXXXX="" XXXXX="" marketing,="" XXXXXXXXX="" XXXXXXXXXXX="" XXXXXXXX.="" XXXXXXX,="" recruitment,="" order="" a="" XXXXXXX="" XXXXXXX="" XXXX="" comprising="" researchers,="" biochemists,="" bio-engineers="" XXXXXXX="" able="" XXXXXXX="" XXXXXXXX="" XXXXXXXXX="" produce="" XXXXX="" anti-XXXXX-drug-resistant="" bacteria="" XXXX="" publish="" renowned="" journals="" XXXXXX="" motif="" XXX="" XXXXX="" XX="" forefront="" innovative="" XXXXXXXXXXXXXXXXX="" research.=""></span></p>The organization’s main activities XXX in XXXXXXXX and development, clinical trials, XXXXXXXXXX, XXXXXXXXXXXX, XXXXXXXXXXXXX, branding XXX XXXXXX recruitment. Foremost, the company XXXXXXX heavily in research XXX XXXXXXXXXXX, XXXXXXXXXX through its XXXX XXXXXXX candidate XX XXXXXXXX, for uses XXXX XX acute bacterial XXXX and XXXX structure XXXXXXXXXX (XXXXXX), hospital XXXXXXXX XXXXXXXXX XXXXXXXXX (XXXX), and ventilor XXXXXXXXXX bacterial XXXXXXXXX (XXXX). (XXXXX XXX, 2019) The XXXXXXX then XXXXXXXX clinical trials to ensure XXXXX XXXXXXXX are safe XXX administration XX XXXXXXXX in XXXXXXXXXX XXXX XX XXXXXXXXX infections XXX XXXX surgeries. For XXXXXXX, XX date, XXX XXXXXXX has XXXXXXXXX XXXXXX on XXXXXX X,500 patients and healthy volunteers XX XXXXXX the XXXXXXX effectiveness XXX side-effects XX iclaprim, XXX main XXXX XXXXXXXXX. XXXXX XXXXXX include XXXXXX-X, XXXXXX-2 and INSPIRE trials, XXXXX are trials XXX XXXXXX, XXXX and VABP respectively. The XXXXXXX also produces XXX XXXXXXXXXXX these drugs, and XX responsible for the safe, efficient and XXXX-XXXXXXXXX XXXXXXXXXX XXX distribution XX their XXXXXXXX to XXXXXXXXXXXX such XX clinics and XXXXXXXXX. The XXXXXXX XXXX XXXXX to certify XXX products to ensure XXXX XXXX can XX distributed legally, XXXXXXX XXXXXXXXXXXXX XXXXXXXXX such as the XXXXXXXXX XXXXXXXXXX XXXXXXX XXXXXXX (QIDP) XXX XXXXXXXXXXXXX. (Motif XXX, XXXX) Next, XXX company has to XXXXX XXX products properly XXX XXXXXXXXXX public acceptance, XXXXXXX means such XX LinkedIn/XXXXXX media XXXXXXXXX, tradeshow XXXXXXXXXXX XXX XXXXXX lectures. XXXXXXX, the company is responsible for talent XXXXXXXXXXX, in order XX ensure XXXX a diverse XXX XXXXXXX team comprising clinical researchers, biochemists, XXX-XXXXXXXXX XXX XXXXXXX XX able to XXXXXXX rigorous XXX XXXXXXXXX research to produce XXXXX XXXX-multi-XXXX-XXXXXXXXX XXXXXXXX drugs, XX XXXX as publish research in renowned journals such as Nature XX XXXXXX that Motif Bio stays at the XXXXXXXXX XX innovative XXXXXXXXXXXXXXXXX XXXXXXXX.<p></p><p>XXX organization XXXXX an important role in XXX U.S. XXXXXXXXXX XXXXXX XX a XXXXXXXXXXXXXXXXX company, and works XXXX XXXXXXXXX, healthcare XXXXXXXXX XXX the government . XXXXXXX have XXXXX that over XX XXXXXXX individuals XXXXXXXX XXX anticipated to die XXXX XXXX-XXXXXXXXX bacterial infections by XXXX, with 23,XXX deaths XXX XXXX in XXX U.S. at present. (Czaplewski and XXXXXXX, XXXX) In XXXXXXXX XX this XXXXXXXX trend, Motif Bio XXX developed XXXXX anti-XXXX antibiotic XXXXXXXXX. XXXX XXXXXX a key role in the X.S. XXXXXXXXXX system, by (a) XXXXXXXX XXX work XX XXXXXXXXXX XXXXXXXXX and hospitals, (b) collaborating with hospitals to XXXXXX XXXX and efficient XXXX trials, XXX (c) XXXXXXX within the XXXXXXXXXX’s support schemes XXX regulatory frameworks XX XXXXXX XXXXXXXXXX compliance. Foremost, Motif Bio XXXXXXX XXX work XX healthcare XXXXXXXXX XXX XXXXXXXXX XX providing novel XXXXXXXXXX solutions XX XXXXXX the XXXXXXX of XXXXX-XXXX resistant bacteria. (XXXXXX, 2007) This has XXX effect of XXXXXXXX XXXX to XXXX XXXXX, provide XXXX effective treatment, XXXXX out XXXX infection risk XXXXXXXXXX XXXX as XXXXXXXXX, XXX XXXX costs XX multi-drug resistant XXXXXXXXXXXXX infections. Secondly, XXXXX XXX XXXXX with hospitals XX XXXXXXX safe XXX XXXXXXXXX XXXX XXXXXX XX XXXXXXXXXX XXXXXXXX. Finally, XXX government supports Motif Bio’s work XXXXXXX XXXXXXXXXXXX XXXXXXXXXX frameworks XXX XXXXXXXXX subsidies.<br></p><p></p><p><br></p><p>In conclusion, Motif XXX, like other innovative XXXXXXXXXXXXXX XXXXXXXXX, XXXXX an XXXXXXXXX XXXX in the U.S. XXXXXXXXXX system XXXXXXX XXX work XX researching XXX XXXXXXXXX XXXXX XXXXXXXXXX solutions to XXXXX-XXXX XXXXXXXXX bacteria.<span XXXXX="Apple-XXXXXXXXX-XXXXX"></span><XX></p> <p><span XXXXX="XX"></span> </p> <p><span class="XX"></span> </p> <p><span XXXXX="XX"></span> </p> <p><span XXXXX="s1"></span> </p> <p><span XXXXX="s1"></span> </p> <p><span XXXXX="s1"></span> </p> <p><span class="XX"></span> </p> <p><span XXXXX="XX"></span> </p> <p><span XXXXX="XX"></span> </p> <p><span class="XX"></span> </p> <p><span XXXXX="XX"></span> </p> <p><span class="XX">XXXXXXXXXX</span></p> <p><span XXXXX="XX"></span> </p> <p><span class="XX">XXXXXXX, N., XXXXXXXXXX, L., & Piddock, X. X. (XXXX). Discovery and development of XXX antibacterial drugs: learning from XXXXXXXXXX?.<i>XXXXXXX XX Antimicrobial XXXXXXXXXXXX</i>,<i>73</i>(X), 1452-1459.</span></p> <p><span class="XX"></span> </p> <p><span class="XX">Motif Bio. (XXXX). XXXXX 3 XXXXX to XXXXXXXX XXXXXX XXX XXXXXXXX of iclaprim versus XXXXXXXXXX for XXXXXX: REVIVE-X (REVIVE-X).<i>ClinicalTrials. XXX XXXXXXXXXX NCT02600611. XXXXX://clinicaltrials. XXX/XXX/show/NCT02600611</i>.</span></p> <p><span XXXXX="XX"></span> </p> <p><span XXXXX="XX">Motif XXX. (XXXX, January XX). XXXXX Motif Bio. XXXXXXXXX XXXX, XXXXX<span class="XXXXX-converted-XXXXX"> </span>17 from <a href="XXXXX://XXX.XXXXXXXX.XXX/XXXXX/"><span XXXXX="s2"></span></a><a XXXX="XXXXX://www.motifbio.com/about/">XXXXX://www.motifbio.XXX/XXXXX/</a></span><span XXXXX="XXXXX-XXXXXXXXX-space"></span></p> <p><span XXXXX="XX"></span> </p> <p><span class="XX">XXXXXXXXX, X., XXXXXX, S., & Islam, K. (XXXX). Iclaprim, a XXXXX diaminopyrimidine with XXXXXX XXXXXXXX XX XXXXXXXXXXXX XXXXXXXXX and resistant bacteria.<i>Bioorganic & XXXXXXXXX XXXXXXXXX XXXXXXX</i>,<i>XX</i>(23), 4217-4221.</span></p> <p><span class="s1"></span> </p> <p><span XXXXX="s1">Wright, G. D., & Sutherland, A. X. (XXXX). XXX XXXXXXXXXX for XXXXXXXXX XXXXXXXXX-XXXXXXXXX XXXXXXXX.<i>Trends in molecular medicine</i>,<i>XX</i>(6), 260-267.</span></p>">
Attachment #1 Preview
